Is Halozyme Therapeutics (HALO) Overvalued After Its New Board Appointment?

Halozyme Therapeutics (HALO) recently drew attention after electing biotechnology and pharmaceutical executive Dannielle Appelhans to its Board of Directors, prompting investors to reassess the stock’s momentum, valuation, and governance profile.

The appointment of Dannielle Appelhans comes as Halozyme Therapeutics trades around US$105.35. The share price return over the past month is up 26.5% and the year to date return is up 49.8%, while the 1 year total shareholder return of 44% and 5 year total shareholder return of about 150% point to strong longer term momentum. Recent Board changes may help investors reassess this in terms of growth potential and execution risk.

Spot emerging momentum stories that share some of Halozyme Therapeutics' quality traits by scanning our hand picked 19 high quality undiscovered gems list.

After Halozyme Therapeutics surged and moved slightly above the average analyst target, while some intrinsic value checks still point to a large discount, where does a reasonable fair value range actually sit for new money today?

Most Popular Narrative: 21.2% Overvalued

Compared with the narrative fair value of $86.89, Halozyme Therapeutics at $105.35 is priced well above that framework, which raises clear valuation questions for investors.

The company's expanding network of global partnerships and the ramp-up of recently launched subcutaneous biologics (e.g., OCREVUS ZUNOVO, Opdivo Qvantig, Tecentriq Hybreza, RYBREVANT SC) provide a robust set of new and diversified royalty streams that are still early in their adoption curve. As these launches mature and penetration increases, especially in emerging and international markets, significant sequential revenue and EBITDA growth is anticipated.

Read the complete narrative.

Curious what kind of revenue build, margin lift and future P/E multiple need to line up to support that fair value gap, especially with today’s higher share price?

Result: Fair Value of $86.89 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors in Halozyme Therapeutics still need to weigh regulatory and reimbursement uncertainty, as well as the company’s reliance on a handful of key royalty partnerships that could shift.

Find out about the key risks to this Halozyme Therapeutics narrative.

Another View: SWS DCF Signals A Very Different Halozyme Therapeutics Story

While the analyst narrative pegs Halozyme Therapeutics at about 21% above its fair value of $86.89, the Simply Wall St DCF model points in the opposite direction. On that cash flow view, HALO at $105.35 is trading well below an estimated value of $406.05, which is a large gap for investors to interpret.

That kind of spread between an earnings based framework and a cash flow based model raises a simple question: which set of assumptions do you trust most when real money is on the line?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Halozyme Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a mixed picture around Halozyme Therapeutics, it makes sense to act while the details are fresh and form your own balanced view. To see both the upside case and the concerns in one place, review the 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Halozyme Therapeutics?

Halozyme Therapeutics may have your attention right now, but you do not want to miss other stocks that could suit your goals just as well.

• Spot potential underpriced opportunities early by reviewing the 45 high quality undervalued stocks before other investors focus on them.
• Strengthen your income stream by checking companies in the 12 dividend fortresses that offer higher yields with supporting fundamentals.
• Protect your downside by focusing on resilient businesses using the 74 resilient stocks with low risk scores that prioritise financial strength and stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com